You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMifepristone
Accession NumberDB00834  (APRD00432)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Structure
Thumb
Synonyms
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
Corlux
Mifegyne
Mifeprex
Mifepriston
Mifepristona
Mifépristone
Mifepristonum
RU-486
RU486
External Identifiers
  • RU-38486
  • RU-486
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KorlymTablet300 mg/1OralCorcept Therapeutics Inc2012-02-17Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CorluxCorcept Therapeutics Incorporated
MefipilAbbott
MifegyneExelgyn Laboratories
MifeprexDanco Laboratories
Brand mixtures
NameLabellerIngredients
MifegymisoLinepharma International Limited
SaltsNot Available
Categories
UNII320T6RNW1F
CAS number84371-65-3
WeightAverage: 429.5937
Monoisotopic: 429.266779369
Chemical FormulaC29H35NO2
InChI KeyVKHAHZOOUSRJNA-GCNJZUOMSA-N
InChI
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
IUPAC Name
(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1,6-dien-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[[email protected]](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Pharmacology
IndicationFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
Structured Indications
PharmacodynamicsMifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Mechanism of actionThe anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Progesterone receptorProteinyes
antagonist
HumanP06401 details
Glucocorticoid receptorProteinyes
antagonist
HumanP04150 details
Related Articles
AbsorptionThe absolute bioavailability of a 20 mg oral dose is 69%
Volume of distributionNot Available
Protein binding98% (bound to plasma proteins, albumin and a 1-acid glycoprotein)
Metabolism

Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.

Route of eliminationFecal: 83%; Renal: 9%.
Half life18 hours
ClearanceNot Available
ToxicityNearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe therapeutic efficacy of 16-Bromoepiandrosterone can be decreased when used in combination with Mifepristone.Investigational
19-norandrostenedioneThe therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone.Experimental, Illicit
4-AndrostenedioneThe therapeutic efficacy of 4-Androstenedione can be decreased when used in combination with Mifepristone.Experimental, Illicit
5-androstenedioneThe therapeutic efficacy of 5-androstenedione can be decreased when used in combination with Mifepristone.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Mifepristone.Experimental
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Mifepristone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Mifepristone.Approved
AceclofenacThe serum concentration of Aceclofenac can be increased when it is combined with Mifepristone.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Mifepristone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Mifepristone.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Mifepristone.Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mifepristone.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Mifepristone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Mifepristone.Approved
AicarAicar may increase the hypoglycemic activities of Mifepristone.Experimental
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Mifepristone.Approved, Vet Approved
AlclometasoneThe therapeutic efficacy of Alclometasone can be decreased when used in combination with Mifepristone.Approved
AldosteroneThe therapeutic efficacy of Aldosterone can be decreased when used in combination with Mifepristone.Experimental
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Mifepristone.Approved, Illicit
AlfuzosinMifepristone may increase the QTc-prolonging activities of Alfuzosin.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Mifepristone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Mifepristone.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Mifepristone.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Mifepristone.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Mifepristone.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Mifepristone.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational
AmantadineMifepristone may increase the QTc-prolonging activities of Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Mifepristone.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Mifepristone.Approved
AmcinonideThe therapeutic efficacy of Amcinonide can be decreased when used in combination with Mifepristone.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Mifepristone.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Mifepristone.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Mifepristone.Approved
AmiodaroneMifepristone may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Mifepristone.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Mifepristone.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mifepristone.Approved
AmoxapineMifepristone may increase the QTc-prolonging activities of Amoxapine.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Mifepristone.Approved
AnagrelideMifepristone may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe therapeutic efficacy of Anecortave can be decreased when used in combination with Mifepristone.Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Mifepristone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.Approved
ApomorphineMifepristone may increase the QTc-prolonging activities of Apomorphine.Approved, Investigational
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Mifepristone.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Mifepristone.Approved, Investigational
Arachidonic AcidThe serum concentration of Arachidonic Acid can be increased when it is combined with Mifepristone.Experimental
ArformoterolThe serum concentration of Arformoterol can be increased when it is combined with Mifepristone.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Mifepristone.Approved, Investigational
AripiprazoleMifepristone may increase the QTc-prolonging activities of Aripiprazole.Approved, Investigational
Arsenic trioxideMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMifepristone may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMifepristone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Mifepristone.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Mifepristone.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Mifepristone.Approved
AtomoxetineMifepristone may increase the QTc-prolonging activities of Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Mifepristone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Mifepristone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mifepristone.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Mifepristone.Approved
AzithromycinMifepristone may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Mifepristone.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Mifepristone.Investigational
BeclomethasoneThe therapeutic efficacy of Beclomethasone can be decreased when used in combination with Mifepristone.Investigational
Beclomethasone dipropionateThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone.Approved, Investigational
BedaquilineMifepristone may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Mifepristone.Withdrawn
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Mifepristone.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Mifepristone.Approved
BeraprostThe serum concentration of Beraprost can be increased when it is combined with Mifepristone.Investigational
BetamethasoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Mifepristone.Approved, Vet Approved
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Mifepristone.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Mifepristone.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Mifepristone.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Mifepristone.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Mifepristone.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Mifepristone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Mifepristone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mifepristone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mifepristone.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Mifepristone.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Mifepristone.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Mifepristone.Approved
BudesonideThe therapeutic efficacy of Budesonide can be decreased when used in combination with Mifepristone.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Mifepristone.Approved
BuforminBuformin may increase the hypoglycemic activities of Mifepristone.Withdrawn
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Mifepristone.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Mifepristone.Approved
BuserelinMifepristone may increase the QTc-prolonging activities of Buserelin.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Mifepristone.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Mifepristone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mifepristone.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Mifepristone.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Mifepristone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Mifepristone.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Mifepristone.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Mifepristone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Mifepristone.Approved
CandesartanThe serum concentration of Candesartan can be increased when it is combined with Mifepristone.Approved
CarbamazepineThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Mifepristone.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Mifepristone.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Mifepristone.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Mifepristone.Withdrawn
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Mifepristone.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Mifepristone.Experimental
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Mifepristone.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Mifepristone.Approved, Vet Approved
CeritinibMifepristone may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mifepristone.Withdrawn
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Mifepristone.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Mifepristone.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Mifepristone.Approved, Illicit
ChloroquineMifepristone may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Mifepristone.Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Mifepristone.Approved
ChlorpromazineMifepristone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Mifepristone.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Mifepristone.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Mifepristone.Approved, Nutraceutical
CiclesonideThe therapeutic efficacy of Ciclesonide can be decreased when used in combination with Mifepristone.Approved, Investigational
CiglitazoneCiglitazone may increase the hypoglycemic activities of Mifepristone.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Mifepristone.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Mifepristone.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Mifepristone.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Mifepristone.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Withdrawn
CiprofloxacinMifepristone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMifepristone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Mifepristone.Approved
CitalopramMifepristone may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMifepristone may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Mifepristone can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Mifepristone.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Mifepristone.Approved, Illicit
ClobetasolThe therapeutic efficacy of Clobetasol can be decreased when used in combination with Mifepristone.Investigational
Clobetasol propionateThe therapeutic efficacy of Clobetasol propionate can be decreased when used in combination with Mifepristone.Approved
ClocortoloneThe therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone.Approved
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Mifepristone.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Mifepristone.Approved
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Mifepristone.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Mifepristone.Approved, Investigational
ClomipramineMifepristone may increase the QTc-prolonging activities of Clomipramine.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Mifepristone.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Mifepristone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Mifepristone.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Mifepristone.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Mifepristone.Approved, Illicit
ClotrimazoleThe metabolism of Mifepristone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineMifepristone may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Mifepristone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mifepristone.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Mifepristone.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Mifepristone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mifepristone.Approved
ConivaptanThe serum concentration of Mifepristone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mifepristone.Approved
Cortisone acetateThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Mifepristone.Approved
CrizotinibMifepristone may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Mifepristone.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Mifepristone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Mifepristone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Mifepristone.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Mifepristone.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Mifepristone.Approved
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Mifepristone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Mifepristone.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.Investigational
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Mifepristone.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Mifepristone.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Mifepristone.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Mifepristone.Approved
DasatinibMifepristone may increase the QTc-prolonging activities of Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Mifepristone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Mifepristone.Approved
DeferasiroxThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixMifepristone may increase the QTc-prolonging activities of Degarelix.Approved
dehydroepiandrosterone sulfateThe therapeutic efficacy of dehydroepiandrosterone sulfate can be decreased when used in combination with Mifepristone.Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Mifepristone.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Mifepristone.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Mifepristone.Investigational
DesfluraneMifepristone may increase the QTc-prolonging activities of Desflurane.Approved
DesipramineMifepristone may increase the QTc-prolonging activities of Desipramine.Approved
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Mifepristone.Approved
DesoximetasoneThe therapeutic efficacy of Desoximetasone can be decreased when used in combination with Mifepristone.Approved
Desoxycorticosterone acetateThe therapeutic efficacy of Desoxycorticosterone acetate can be decreased when used in combination with Mifepristone.Approved
Desoxycorticosterone PivalateThe therapeutic efficacy of Desoxycorticosterone Pivalate can be decreased when used in combination with Mifepristone.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Mifepristone.Approved
DexamethasoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe therapeutic efficacy of Dexamethasone isonicotinate can be decreased when used in combination with Mifepristone.Vet Approved
DexketoprofenThe therapeutic efficacy of Mifepristone can be decreased when used in combination with Dexketoprofen.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Mifepristone.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Mifepristone.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mifepristone.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Mifepristone.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Mifepristone.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Mifepristone.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Mifepristone.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Mifepristone.Approved
DiflorasoneThe therapeutic efficacy of Diflorasone can be decreased when used in combination with Mifepristone.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Mifepristone.Approved
DifluocortoloneThe therapeutic efficacy of Difluocortolone can be decreased when used in combination with Mifepristone.Approved
DifluprednateThe therapeutic efficacy of Difluprednate can be decreased when used in combination with Mifepristone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Mifepristone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mifepristone.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Mifepristone.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Mifepristone.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Mifepristone.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Mifepristone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Mifepristone.Approved
DisopyramideMifepristone may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Mifepristone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mifepristone.Approved, Investigational
DofetilideMifepristone may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMifepristone may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Mifepristone.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Mifepristone.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Mifepristone.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Mifepristone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mifepristone.Approved, Investigational
DoxycyclineThe metabolism of Mifepristone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Mifepristone.Approved, Illicit
DronedaroneMifepristone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMifepristone may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Mifepristone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Mifepristone.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Mifepristone.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Mifepristone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mifepristone.Approved
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mifepristone.Approved, Investigational
EliglustatMifepristone may increase the QTc-prolonging activities of Eliglustat.Approved
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Mifepristone.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Mifepristone.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Mifepristone.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Mifepristone.Approved, Vet Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Mifepristone.Approved
EnzalutamideThe serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Mifepristone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Mifepristone.Approved
EpoprostenolThe serum concentration of Epoprostenol can be increased when it is combined with Mifepristone.Approved
EquileninThe therapeutic efficacy of Equilenin can be decreased when used in combination with Mifepristone.Experimental
EquilinThe therapeutic efficacy of Equilin can be decreased when used in combination with Mifepristone.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Mifepristone.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Mifepristone.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Mifepristone.Approved
EribulinMifepristone may increase the QTc-prolonging activities of Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mifepristone.Approved, Investigational
ErythromycinMifepristone may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramMifepristone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Mifepristone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Mifepristone.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Mifepristone.Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Mifepristone.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Mifepristone.Approved, Vet Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Mifepristone.Approved
EstroneThe therapeutic efficacy of Estrone can be decreased when used in combination with Mifepristone.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Mifepristone.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Mifepristone.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Mifepristone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mifepristone.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Mifepristone.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Mifepristone.Approved
EtodolacThe serum concentration of Etodolac can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Mifepristone.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Mifepristone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mifepristone.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Mifepristone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Mifepristone.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mifepristone.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Mifepristone.Approved, Investigational
ExenatideExenatide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Mifepristone.Approved
EzogabineMifepristone may increase the QTc-prolonging activities of Ezogabine.Approved
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Mifepristone.Approved
FamotidineMifepristone may increase the QTc-prolonging activities of Famotidine.Approved
FelbamateMifepristone may increase the QTc-prolonging activities of Felbamate.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Mifepristone.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Mifepristone.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Mifepristone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Mifepristone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Mifepristone.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Mifepristone.Approved
FingolimodMifepristone may increase the QTc-prolonging activities of Fingolimod.Approved, Investigational
FlecainideMifepristone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Mifepristone.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Mifepristone.Approved
fluasteroneThe therapeutic efficacy of fluasterone can be decreased when used in combination with Mifepristone.Investigational
FluconazoleMifepristone may increase the QTc-prolonging activities of Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Mifepristone.Withdrawn
FlumethasoneThe therapeutic efficacy of Flumethasone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Mifepristone.Approved
FlunisolideThe therapeutic efficacy of Flunisolide can be decreased when used in combination with Mifepristone.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Mifepristone.Approved, Illicit
Fluocinolone AcetonideThe therapeutic efficacy of Fluocinolone Acetonide can be decreased when used in combination with Mifepristone.Approved, Investigational, Vet Approved
FluocinonideThe therapeutic efficacy of Fluocinonide can be decreased when used in combination with Mifepristone.Approved, Investigational
FluocortoloneThe therapeutic efficacy of Fluocortolone can be decreased when used in combination with Mifepristone.Approved, Withdrawn
FluorometholoneThe therapeutic efficacy of Fluorometholone can be decreased when used in combination with Mifepristone.Approved
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Mifepristone.Approved
FluoxetineMifepristone may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Mifepristone.Approved, Illicit
FlupentixolMifepristone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe therapeutic efficacy of Fluprednidene can be decreased when used in combination with Mifepristone.Approved, Withdrawn
FluprednisoloneThe therapeutic efficacy of Fluprednisolone can be decreased when used in combination with Mifepristone.Approved
FlurandrenolideThe therapeutic efficacy of Flurandrenolide can be decreased when used in combination with Mifepristone.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Mifepristone.Approved, Illicit
FlurbiprofenThe serum concentration of Flurbiprofen can be increased when it is combined with Mifepristone.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Mifepristone.Approved
Fluticasone furoateThe therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Mifepristone.Approved
Fluticasone PropionateThe therapeutic efficacy of Fluticasone Propionate can be decreased when used in combination with Mifepristone.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Mifepristone.Approved
FluvoxamineThe metabolism of Mifepristone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe therapeutic efficacy of Formestane can be decreased when used in combination with Mifepristone.Approved, Investigational, Withdrawn
FormoterolThe serum concentration of Formoterol can be increased when it is combined with Mifepristone.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Mifepristone.Approved
FosaprepitantThe serum concentration of Mifepristone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetMifepristone may increase the QTc-prolonging activities of Foscarnet.Approved
FosphenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Mifepristone.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Mifepristone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Mifepristone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidMifepristone may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineMifepristone may increase the QTc-prolonging activities of Galantamine.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Mifepristone.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
GavestinelThe serum concentration of Gavestinel can be increased when it is combined with Mifepristone.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mifepristone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Mifepristone.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Mifepristone.Approved
GemifloxacinMifepristone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Mifepristone.Approved
GlibornurideGlibornuride may increase the hypoglycemic activities of Mifepristone.Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Mifepristone.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Mifepristone.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Mifepristone.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Mifepristone.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Mifepristone.Approved
GoserelinMifepristone may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMifepristone may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Mifepristone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Mifepristone.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Mifepristone.Approved, Investigational
GusperimusGusperimus may increase the hypoglycemic activities of Mifepristone.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Mifepristone.Approved
HaloperidolMifepristone may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Mifepristone.Approved, Vet Approved
HE3286The therapeutic efficacy of HE3286 can be decreased when used in combination with Mifepristone.Investigational
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Mifepristone.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Mifepristone.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Mifepristone.Approved
HistrelinMifepristone may increase the QTc-prolonging activities of Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Mifepristone.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Mifepristone.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Mifepristone.Approved
HydroxyzineMifepristone may increase the QTc-prolonging activities of Hydroxyzine.Approved
IbandronateMifepristone may increase the QTc-prolonging activities of Ibandronate.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Mifepristone.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Mifepristone.Approved
IbutilideMifepristone may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Mifepristone.Approved
IdelalisibThe serum concentration of Mifepristone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Mifepristone.Approved
IloperidoneMifepristone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mifepristone.Approved
ImipramineMifepristone may increase the QTc-prolonging activities of Imipramine.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Mifepristone.Approved, Investigational
IndacaterolMifepristone may increase the QTc-prolonging activities of Indacaterol.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Mifepristone.Investigational, Withdrawn
IndapamideMifepristone may increase the QTc-prolonging activities of Indapamide.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Mifepristone.Approved
indisulamThe serum concentration of indisulam can be increased when it is combined with Mifepristone.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Mifepristone.Approved, Investigational
Insulin AspartMifepristone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMifepristone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Mifepristone.Approved
Insulin GlulisineMifepristone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Mifepristone.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Mifepristone.Approved
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Mifepristone.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Mifepristone.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Mifepristone.Withdrawn
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Mifepristone.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mifepristone.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Mifepristone.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Mifepristone.Approved
IsofluraneMifepristone may increase the QTc-prolonging activities of Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Mifepristone.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Mifepristone.Approved
IsradipineMifepristone may increase the QTc-prolonging activities of Isradipine.Approved
IstaroximeThe therapeutic efficacy of Istaroxime can be decreased when used in combination with Mifepristone.Investigational
ItraconazoleMifepristone may increase the QTc-prolonging activities of Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Mifepristone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Mifepristone.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Mifepristone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Mifepristone.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Mifepristone.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Mifepristone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Mifepristone.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Mifepristone.Approved
KetoconazoleMifepristone may increase the QTc-prolonging activities of Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be increased when it is combined with Mifepristone.Approved, Vet Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Mifepristone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Mifepristone.Approved, Investigational
LanreotideMifepristone may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mifepristone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Mifepristone.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Mifepristone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Mifepristone.Approved
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Mifepristone.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Mifepristone.Approved
LenvatinibMifepristone may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Mifepristone.Approved, Investigational
LesinuradThe serum concentration of Lesinurad can be increased when it is combined with Mifepristone.Approved
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Mifepristone.Approved, Investigational
LeuprolideMifepristone may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Mifepristone.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Mifepristone.Approved
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Mifepristone.Approved
LevofloxacinMifepristone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Mifepristone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mifepristone.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Mifepristone.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Mifepristone.Approved
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Mifepristone.Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Mifepristone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.Approved
LiraglutideLiraglutide may increase the hypoglycemic activities of Mifepristone.Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Mifepristone.Approved
LithiumMifepristone may increase the QTc-prolonging activities of Lithium.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Mifepristone.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Mifepristone.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Mifepristone.Approved
LopinavirMifepristone may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Mifepristone.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Mifepristone.Approved
LornoxicamThe serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Mifepristone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Mifepristone.Approved, Investigational
LuliconazoleThe serum concentration of Mifepristone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mifepristone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineMifepristone may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Mifepristone.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Mifepristone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Mifepristone.Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Mifepristone.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Mifepristone.Approved, Investigational
MaprotilineMifepristone may increase the QTc-prolonging activities of Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Mifepristone.Approved, Investigational
ME-609The therapeutic efficacy of ME-609 can be decreased when used in combination with Mifepristone.Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Mifepristone.Withdrawn
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Mifepristone.Approved, Vet Approved
MecaserminMifepristone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Mifepristone.Approved, Investigational
MedrysoneThe therapeutic efficacy of Medrysone can be decreased when used in combination with Mifepristone.Approved
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Mifepristone.Approved
MefloquineMifepristone may increase the QTc-prolonging activities of Mefloquine.Approved
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Mifepristone.Approved, Nutraceutical, Vet Approved
MelengestrolThe therapeutic efficacy of Melengestrol can be decreased when used in combination with Mifepristone.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Mifepristone.Approved, Vet Approved
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Mifepristone.Investigational, Withdrawn
MesalazineMesalazine may increase the hypoglycemic activities of Mifepristone.Approved
MestranolThe serum concentration of Mestranol can be increased when it is combined with Mifepristone.Approved
MetforminMetformin may increase the hypoglycemic activities of Mifepristone.Approved
MethadoneMifepristone may increase the QTc-prolonging activities of Methadone.Approved
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Mifepristone.Experimental
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Mifepristone.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Mifepristone.Approved
MethotrimeprazineMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.Approved
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Mifepristone.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Mifepristone.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Mifepristone.Investigational
MethylprednisoloneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Mifepristone.Approved
MetoclopramideMifepristone may increase the QTc-prolonging activities of Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Mifepristone.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Mifepristone.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Mifepristone.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Mifepristone.Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mifepristone.Approved, Illicit
MiglitolMiglitol may increase the hypoglycemic activities of Mifepristone.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Mifepristone.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Mifepristone.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Mifepristone.Approved
MirabegronMifepristone may increase the QTc-prolonging activities of Mirabegron.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Mifepristone.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Mifepristone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Mifepristone.Approved, Investigational
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Mifepristone.Approved
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Mifepristone.Approved, Investigational
MoexiprilMifepristone may increase the QTc-prolonging activities of Moexipril.Approved
MometasoneThe therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Mifepristone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Mifepristone.Approved, Investigational
MoxifloxacinMifepristone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
muraglitazarThe serum concentration of muraglitazar can be increased when it is combined with Mifepristone.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mifepristone.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Mifepristone.Approved
NafcillinThe serum concentration of Mifepristone can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Mifepristone.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mifepristone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Mifepristone.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Mifepristone.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Mifepristone.Approved, Investigational
NCX 1022The therapeutic efficacy of NCX 1022 can be decreased when used in combination with Mifepristone.Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Mifepristone.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Mifepristone.Approved, Withdrawn
NelfinavirMifepristone may increase the QTc-prolonging activities of Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Mifepristone.Investigational
NetupitantThe serum concentration of Netupitant can be increased when it is combined with Mifepristone.Approved
NevirapineThe serum concentration of Mifepristone can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Mifepristone.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Mifepristone.Approved
NiclosamideThe serum concentration of Niclosamide can be increased when it is combined with Mifepristone.Approved, Vet Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Mifepristone.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mifepristone.Approved
NilotinibMifepristone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Mifepristone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Mifepristone.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Mifepristone.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Mifepristone.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Mifepristone.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Mifepristone.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Mifepristone.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Mifepristone.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Mifepristone.Approved
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Mifepristone.Approved
NorfloxacinMifepristone may increase the QTc-prolonging activities of Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Mifepristone.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Mifepristone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Mifepristone.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Mifepristone.Withdrawn
OctreotideMifepristone may increase the QTc-prolonging activities of Octreotide.Approved, Investigational
OfloxacinMifepristone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineMifepristone may increase the QTc-prolonging activities of Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Mifepristone.Approved
Oleoyl estroneThe therapeutic efficacy of Oleoyl estrone can be decreased when used in combination with Mifepristone.Investigational
OlodaterolThe serum concentration of Olodaterol can be increased when it is combined with Mifepristone.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Mifepristone.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Mifepristone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Mifepristone.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
OndansetronMifepristone may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Mifepristone.Approved
OsimertinibThe serum concentration of Mifepristone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Mifepristone.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
OxaprozinThe serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Mifepristone.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Mifepristone.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Mifepristone.Approved, Illicit
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
OxytocinMifepristone may increase the QTc-prolonging activities of Oxytocin.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Mifepristone.Approved
PaliperidoneMifepristone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Mifepristone.Approved, Investigational
PanobinostatMifepristone may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Mifepristone.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Mifepristone.Approved
ParamethasoneThe therapeutic efficacy of Paramethasone can be decreased when used in combination with Mifepristone.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Mifepristone.Approved
PargylinePargyline may increase the hypoglycemic activities of Mifepristone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Mifepristone.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Mifepristone.Approved
ParoxetineMifepristone may increase the QTc-prolonging activities of Paroxetine.Approved, Investigational
PasireotideMifepristone may increase the QTc-prolonging activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mifepristone.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Mifepristone.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Mifepristone.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Mifepristone.Approved
PentamidineMifepristone may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe serum concentration of Mifepristone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Mifepristone.Approved
PerflutrenMifepristone may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Mifepristone.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Mifepristone.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Mifepristone.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mifepristone.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Mifepristone.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Mifepristone.Withdrawn
PhenelzinePhenelzine may increase the hypoglycemic activities of Mifepristone.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Mifepristone.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Mifepristone.Withdrawn
PhenobarbitalThe serum concentration of Mifepristone can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Mifepristone.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Mifepristone.Withdrawn
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Mifepristone.Approved
PhenylbutazoneThe serum concentration of Phenylbutazone can be increased when it is combined with Mifepristone.Approved, Vet Approved
PhenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Mifepristone.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Mifepristone.Approved, Investigational
PimozideMifepristone may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Mifepristone.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Mifepristone.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Mifepristone.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Mifepristone.Approved
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mifepristone.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Mifepristone.Withdrawn
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Mifepristone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Mifepristone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Mifepristone.Approved
PosaconazoleMifepristone may increase the QTc-prolonging activities of Posaconazole.Approved, Investigational, Vet Approved
PramlintidePramlintide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
PrasteroneThe therapeutic efficacy of Prasterone can be decreased when used in combination with Mifepristone.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Mifepristone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mifepristone.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Mifepristone.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Mifepristone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Mifepristone.Approved
PrednicarbateThe therapeutic efficacy of Prednicarbate can be decreased when used in combination with Mifepristone.Approved
PrednisoloneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Prednisone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
PregnenoloneThe therapeutic efficacy of Pregnenolone can be decreased when used in combination with Mifepristone.Experimental
PrimaquineMifepristone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Mifepristone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideMifepristone may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Mifepristone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Mifepristone.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Mifepristone.Approved
PromazineMifepristone may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineMifepristone may increase the QTc-prolonging activities of Promethazine.Approved
PropafenoneMifepristone may increase the QTc-prolonging activities of Propafenone.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Mifepristone.Approved, Investigational
ProtriptylineMifepristone may increase the QTc-prolonging activities of Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mifepristone.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Mifepristone.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Mifepristone.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Mifepristone.Approved, Illicit
QuetiapineMifepristone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Mifepristone.Approved
QuinidineMifepristone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMifepristone may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Mifepristone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Mifepristone.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Mifepristone.Approved
RanolazineMifepristone may increase the QTc-prolonging activities of Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Mifepristone.Approved
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Mifepristone.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Mifepristone.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Mifepristone.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Mifepristone.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Mifepristone.Approved
RifabutinThe serum concentration of Mifepristone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Mifepristone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Mifepristone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mifepristone.Approved, Investigational
RilpivirineMifepristone may increase the QTc-prolonging activities of Rilpivirine.Approved
RimexoloneThe therapeutic efficacy of Rimexolone can be decreased when used in combination with Mifepristone.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Mifepristone.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Mifepristone.Approved
RisperidoneMifepristone may increase the QTc-prolonging activities of Risperidone.Approved, Investigational
RitonavirMifepristone may increase the QTc-prolonging activities of Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Mifepristone.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Mifepristone.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Mifepristone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Mifepristone.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Mifepristone.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Mifepristone.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Mifepristone.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Mifepristone.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Mifepristone.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Mifepristone.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Mifepristone.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Mifepristone.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Mifepristone.Withdrawn
SalbutamolMifepristone may increase the QTc-prolonging activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Mifepristone.Approved, Vet Approved
SalmeterolMifepristone may increase the QTc-prolonging activities of Salmeterol.Approved
SaquinavirMifepristone may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Mifepristone.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Mifepristone.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Mifepristone.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Mifepristone.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Mifepristone.Approved
SevofluraneMifepristone may increase the QTc-prolonging activities of Sevoflurane.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Mifepristone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.Approved
SiltuximabThe serum concentration of Mifepristone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Mifepristone.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Mifepristone.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Mifepristone.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Mifepristone.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Mifepristone.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Mifepristone.Approved
SolifenacinMifepristone may increase the QTc-prolonging activities of Solifenacin.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Mifepristone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Mifepristone.Approved, Investigational
SotalolMifepristone may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Mifepristone.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Mifepristone.Experimental
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Mifepristone.Approved
St. John's WortThe serum concentration of Mifepristone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Mifepristone.Approved, Vet Approved
StiripentolThe serum concentration of Mifepristone can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Mifepristone.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Mifepristone.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Mifepristone.Approved
SulfamoxoleThe serum concentration of Sulfamoxole can be increased when it is combined with Mifepristone.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Mifepristone.Approved
SulfisoxazoleMifepristone may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
SunitinibMifepristone may increase the QTc-prolonging activities of Sunitinib.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be increased when it is combined with Mifepristone.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Mifepristone.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Mifepristone.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Mifepristone.Approved
TacrolimusMifepristone may increase the QTc-prolonging activities of Tacrolimus.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Mifepristone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Mifepristone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mifepristone.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Mifepristone.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Mifepristone.Approved
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Mifepristone.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Mifepristone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Mifepristone.Experimental
TazaroteneThe serum concentration of Tazarotene can be increased when it is combined with Mifepristone.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Mifepristone.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Mifepristone.Approved
TelavancinMifepristone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMifepristone may increase the QTc-prolonging activities of Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Mifepristone.Withdrawn
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Mifepristone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mifepristone.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Mifepristone.Approved
TenoxicamThe serum concentration of Tenoxicam can be increased when it is combined with Mifepristone.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Mifepristone.Approved, Investigational, Vet Approved
TerbutalineMifepristone may increase the QTc-prolonging activities of Terbutaline.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Mifepristone.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Mifepristone.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Mifepristone.Approved, Investigational
TetrabenazineMifepristone may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Mifepristone.Approved, Vet Approved
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Mifepristone.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Mifepristone.Approved
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Mifepristone.Approved, Vet Approved
ThiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Mifepristone.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mifepristone.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Mifepristone.Approved
ThiothixeneMifepristone may increase the QTc-prolonging activities of Thiothixene.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Mifepristone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Mifepristone.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Mifepristone.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Mifepristone.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Mifepristone.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Mifepristone.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Mifepristone.Approved, Investigational
TixocortolThe therapeutic efficacy of Tixocortol can be decreased when used in combination with Mifepristone.Approved
TizanidineMifepristone may increase the QTc-prolonging activities of Tizanidine.Approved
TocilizumabThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Mifepristone.Approved, Investigational
TolazamideMifepristone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Mifepristone.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Mifepristone.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Mifepristone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mifepristone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mifepristone.Approved, Investigational
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.Approved
ToremifeneMifepristone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Mifepristone.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Mifepristone.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mifepristone.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Mifepristone.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Mifepristone.Approved
TrazodoneMifepristone may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Mifepristone.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Mifepristone.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Triamcinolone can be decreased when used in combination with Mifepristone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Mifepristone.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Mifepristone.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Mifepristone.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.Approved
TriptorelinMifepristone may increase the QTc-prolonging activities of Triptorelin.Approved, Vet Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Mifepristone.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Mifepristone.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Withdrawn
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Mifepristone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mifepristone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Mifepristone.Approved
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Mifepristone.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Mifepristone.Approved, Investigational
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Mifepristone.Approved, Investigational
VandetanibMifepristone may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Mifepristone.Investigational
VardenafilMifepristone may increase the QTc-prolonging activities of Vardenafil.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Mifepristone.Approved
VemurafenibMifepristone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Mifepristone.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mifepristone.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Mifepristone.Investigational
VilanterolMifepristone may increase the QTc-prolonging activities of Vilanterol.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Mifepristone.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mifepristone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Mifepristone.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Mifepristone.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Mifepristone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Mifepristone.Approved
VogliboseVoglibose may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Mifepristone.Approved, Investigational
VorinostatMifepristone may increase the QTc-prolonging activities of Vorinostat.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Mifepristone.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Mifepristone.Approved
XimelagatranThe serum concentration of Ximelagatran can be increased when it is combined with Mifepristone.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Mifepristone.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Mifepristone.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Mifepristone.Approved
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Mifepristone.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Zaltoprofen can be increased when it is combined with Mifepristone.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Mifepristone.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Mifepristone.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hypoglycemic activities of Mifepristone.Withdrawn
ZiprasidoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Mifepristone.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Mifepristone.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Mifepristone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Mifepristone.Approved
ZuclopenthixolMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Narendra Joshi, Anil Khile, Nitin Pradhan, “Novel polymorph form M of mifepristone and process for its preparation.” U.S. Patent US20070105828, issued May 10, 2007.

US20070105828
General References
  1. Fiala C, Gemzel-Danielsson K: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006 Jul;74(1):66-86. Epub 2006 May 19. [PubMed:16781264 ]
  2. Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003 Dec;68(6):421-6. [PubMed:14698071 ]
  3. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun;11(3):293-307. Epub 2005 Mar 24. [PubMed:15790602 ]
  4. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. [PubMed:9562577 ]
  5. Piaggio G, von Hertzen H, Heng Z, Bilian X, Cheng L: Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003 Dec;68(6):447-52. [PubMed:14698075 ]
External Links
ATC CodesG03XB01G03XB51
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (46.5 KB)
MSDSDownload (57.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7135
Caco-2 permeable+0.6716
P-glycoprotein substrateSubstrate0.643
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7606
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.8334
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6293
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6129
Ames testNon AMES toxic0.856
CarcinogenicityNon-carcinogens0.825
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity2.7705 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9177
hERG inhibition (predictor II)Non-inhibitor0.6879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Danco laboratories llc
Packagers
  • Danco Labs LLC
Dosage forms
FormRouteStrength
TabletOral300 mg/1
Kit; tabletBuccal; Oral
Prices
Unit descriptionCostUnit
Mifeprex 200 mg tablet90.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8921348 No2008-08-272028-08-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-196 °CFDA Label
water solubilityPoorly solubleFDA Label
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00336 mg/mLALOGPS
logP5.33ALOGPS
logP5.13ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)12.87ChemAxon
pKa (Strongest Basic)4.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity132.58 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassOxosteroids
Direct ParentOxosteroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • Substituted aniline
  • Dialkylarylamine
  • Aniline
  • Benzenoid
  • Ynone
  • Monocyclic benzene moiety
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, Wallwiener D: Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod. 1999 Jan;14(1):198-206. [PubMed:10374120 ]
  2. Sun M, Zhu G, Zhou L: [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]. Zhonghua Fu Chan Ke Za Zhi. 1998 Apr;33(4):227-31. [PubMed:10682471 ]
  3. Hazra BG, Basu S, Pore VS, Joshi PL, Pal D, Chakrabarti P: Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486). Steroids. 2000 Mar;65(3):157-62. [PubMed:10699595 ]
  4. Gao Y, Cheng L, Liu Y: [Failure of mifepristone induced interruption of pregnancy: point mutation at genetic codon 722 in human progesterone receptor gene]. Zhonghua Fu Chan Ke Za Zhi. 1998 Sep;33(9):549-52. [PubMed:10806733 ]
  5. Jiang J, Wu R, Wang Z: [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria]. Zhonghua Fu Chan Ke Za Zhi. 2001 Apr;36(4):218-21. [PubMed:11783365 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. LeVan TD, Babin EA, Yamamura HI, Bloom JW: Pharmacological characterization of glucocorticoid receptors in primary human bronchial epithelial cells. Biochem Pharmacol. 1999 May 1;57(9):1003-9. [PubMed:10796070 ]
  2. Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. [PubMed:15120421 ]
  3. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699 ]
  4. Gu G, Hentunen TA, Nars M, Harkonen PL, Vaananen HK: Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis. 2005 May;10(3):583-95. [PubMed:15909120 ]
  5. de Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A: Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006 May 24;26(21):5709-19. [PubMed:16723527 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994 Nov 28;355(2):187-91. [PubMed:7982498 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:44